Skip to main content
. 2021 Mar 23;13(6):1483. doi: 10.3390/cancers13061483

Figure 7.

Figure 7

Analysis of cross-resistance between Abiraterone and Enzalutamide from the concomitant cellular models (R-ADT/NHAs + Abiraterone or Enzalutamide). In order to study the cross-resistance to the complementary antiandrogen, R-ADT/E cells were treated with AA (20 μM) (R-ADT/E + Abiraterone), the R-ADT/A cell line was exposed to Enz (40 μM) for 5 days (R-ADT/AA + Enzalutamide), and cell growth was evaluated by xCELLigence. (A) Cell proliferation analysis results for LNCaP cell lines using xCELLigence. Results have been standardized considering the final value after 5 days R-ADT/NHAs cell lines to 100%. LNCaP R-ADT/E + Abiraterone (left panel) and LNCaP R-ADT/A + Enzalutamide (right panel). Data shown correspond to the mean ± SD calculated from the quadruplicates made for each condition. (B) qPCR analysis for AR isoforms and AR target genes. The results are shown normalized with respect to endogenous control (GADPH). The error bars shown correspond to the SD calculated from triplicates. (C) Cell proliferation assays and (D) qPCR analysis for 22RV1 R-ADT/E + Abiraterone (left panels) and 22RV1 R-ADT/A + Enzalutamide (right panels).